3D Biomimetic Models to Reconstitute Tumor Microenvironment In Vitro: Spheroids, Organoids, and Tumor‐on‐a‐Chip
Open accessThe DOI matches its Crossref record; 199 of the 200 references it cites were found in a registry or an index; 79 of the 184 sources its claims cite were checked for support.
Abstract
Decades of efforts in engineering in vitro cancer models have advanced drug discovery and the insight into cancer biology. However, the establishment of preclinical models that enable fully recapitulating the tumor microenvironment remains challenging owing to its intrinsic complexity. Recent progress in engineering techniques has allowed the development of a new generation of in vitro preclinical models that can recreate complex in vivo tumor microenvironments and accurately predict drug responses, including spheroids, organoids, and tumor-on-a-chip. These biomimetic 3D tumor models are of particular interest as they pave the way for better understanding of cancer biology and accelerating the development of new anticancer therapeutics with reducing animal use. Here, the recent advances in developing these in vitro platforms for cancer modeling and preclinical drug screening, focusing on incorporating hydrogels are reviewed to reconstitute physiologically relevant microenvironments. The combination of spheroids/organoids with microfluidic technologies is also highlighted to better mimic in vivo tumors and discuss the challenges and future directions in the clinical translation of such models for drug screening and personalized medicine.
Overview
CoChat Summary
## TL;DR
This paper is a review of 3D biomimetic in vitro cancer models—spheroids, organoids, and tumor-on-a-chip—aimed at better reconstituting the tumor microenvironment (TME) for cancer biology and drug screening. It argues that these models can better capture ECM, hypoxia, interstitial flow, and multicellular interactions than 2D culture, while highlighting challenges for clinical translation and personalized medicine.
## Key findings
- The paper states that 2D monolayer models cannot recreate the complex tumor microenvironment, and that animal models are low throughput, time-consuming, costly, and limited by murine physiology; it notes that less than 4% of anticancer drug candidates pass clinical trials to FDA approval.
- 3D tumor spheroids can exceed 400 µm and develop in vivo-like oxygen/nutrient gradients with a necrotic core, quiescent intermediate region, and proliferating outer shell; they also replicate cell–cell interactions and de novo ECM deposition, and are used for routine drug screening.
- Patient-derived organoids preserve structural and functional features of in vivo tumors and, in one cited platform, supported organoid culture from over 1000 patients; organoids and organoids-on-a-chip are described as promising for predicting patient-specific drug responses.
- Microfluidic tumor-on-a-chip systems are presented as especially useful for modeling metastasis, angiogenesis, BBB transport, and therapy response because they can control fluid flow, multiple cell types, and microenvironmental cues; one BBB nanoparticle transport platform was reported to be faster than a 2D transwell setup (5 min vs 3 h).
## Methods
- Narrative review of recent advances in engineered 3D cancer models, organized around TME components, spheroids, organoids, and tumor-on-a-chip platforms.
- The paper synthesizes examples from prior studies using hydrogel-based systems, microfluidic devices, 3D bioprinting, microwell arrays, and coculture models with cancer, stromal, immune, endothelial, and BBB-related cells.
- It qualitatively compares model features and applications for cancer progression, metastasis, and anticancer drug screening rather than presenting new experimental data.
## Limitations
- The paper states that current 3D models still have limitations before widespread use, including incomplete incorporation of tumor vasculature, limited reproducibility, difficulty with long-term culture, and lack of scalability to high-throughput screening.
- It also states that many models do not fully capture the native TME because of nonstandardized or ill-defined matrices such as Matrigel, insufficient tissue-specific biochemical/biophysical cues, and lack of stromal or immune components.
- Evident from the text: this is a review article, so it does not generate new primary data or directly validate the summarized platforms in a single experimental system.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Spheroid models. a) PDMS‐based microwell arrays for culturing tumor spheroids to monitor the interactions among tumor spheroids, immune cells, and immune checkpoint inhibitors. Reproduced with permission.[ 58 ] Copyright 2021, Wiley‐VCH GmbH. b) Schematic illustration of the fabrication of hydrogel‐based microwell arrays for studying the effect of substrate composition and stiffness on tumor formation. Reproduced with permission.[ 60a ] Copyright 2017, IOP Publishing. c) Spheroids generated in a droplet‐based microfluidic platform for drug‐based cytotoxicity screening (p < 0.05). Reproduced with permission.[ 67 ] Copyright 2016, Royal Society of Chemistry. d) Hybrid hydrogel of collagen and alginate for fabrication of tumor spheroids for drug screening. Reproduced with permission.[ 72 ] Copyright 2017, American Chemical Society. e) Decellularized matrix for preparation of tumor spheroids for high‐throughput drug screening. Scalebars = 400 µm. Reproduced with permission.[ 78 ] Copyright 2021, Elsevier. f) Spheroids‐on‐a‐chip for studying the role of vascular perfusion in drug efficacy. Reproduced with permission.[ 81 ] Copyright 2020, Elsevier.](https://figures.cochat.ai/paper-figures/155e535488174a2fbe294a679725f9a0/3d-biomimetic-models-to-reconstitute-tumor-microenvironment-in-vitro-spheroids-figure-3.jpg)
![Figure 4 Organoid models. a) Schematic illustration of PDX‐derived tumor organoid encapsulated in enzymatically crosslinked HA‐Ph, gelatin‐Ph, or gelatin‐Ph/HA‐Ph hybrid hydrogels with tunable stiffness. Scale bars:100 µm. Reproduced with permission.[ 94 ] Copyright 2019, Elsevier. b) Schematics of ECM‐mimetic EKGel for growth of breast PDOs. Reproduced with permission.[ 96 ] Copyright 2022, Springer Nature. c) Microfluidic‐based organoid culture for drug sensitivity testing. Reproduced with permission.[ 103 ] Copyright 2019, Royal Society of Chemistry. d) Vascularized organoids chips for mimicking physiological delivery of drug to tumor sites. Scale bars:100 µm. Reproduced with permission.[ 104 ] Copyright 2019, Royal Society of Chemistry.](https://figures.cochat.ai/paper-figures/8bd4e1d098ef4dcb8bd82d144e7ecdb1/3d-biomimetic-models-to-reconstitute-tumor-microenvironment-in-vitro-spheroids-figure-4.jpg)
![Figure 5 Microfluidic modeling of tumor metastasis. a) A microfluidic‐based platform for capturing vasculogenic and angiogenic vessel formation. Scale bars:100 µm. Reproduced with permission.[ 112 ] Copyright 2013, Royal Society of Chemistry. b) Microfluidic lumen‐based system for reconstituting angiogenesis in response to different proangiogenic factors. Scale bars:100 µm. Reproduced with permission.[ 114c ] Copyright 2013, National Academy of Sciences. c) Organotypic microfluidic device for investigating tumor invasion in the presence of CAFs. Reproduced with permission.[ 117 ] Copyright 2019, American Association for Cancer Research. d) Schematics of tumor‐immune microenvironment in vitro: tumor spheroids are cocultured with neutrophils separated by porous membrane. Reproduced with permission.[ 123 ]Copyright 2021, IOP Publishing. e) Hydrogel‐based microfluidic platform modeling tumor intravasation. Reproduced with permission.[ 127 ] Copyright 2012, National Academy of Sciences. f) A 3D vascularized microfluidic device replicating the effect of monocytes on tumor cell extravasation. Reproduced with permission.[ 128 ] Copyright 2018, Elsevier.](https://figures.cochat.ai/paper-figures/f1f927abc8bd49949099b861c5abac18/3d-biomimetic-models-to-reconstitute-tumor-microenvironment-in-vitro-spheroids-figure-5.jpg)
![Figure 6 Microfluidic modeling of tumor response to therapeutics. a) Microfluidic invasion model that captures the crosstalk between tumor cells and CAFs for anticancer drug studies. Scale bar is 125 µm. Reproduced with permission.[ 135 ] Copyright 2017, Royal Society of Chemistry. b) Schematics of oxygen gradient‐array microfluidic device for studying the effect of oxygen levels on drug cytotoxicity in tumor spheroids. Reproduced with permission.[ 68a ] Copyright 2021, IOP Publishing. c) Illustration of microfluidic arrays to generate PDOs for developing personalized cancer therapies. Reproduced with permission.[ 106 ] Copyright 2021, Wiley‐VCH GmbH. d) Microfluidic lumen‐based system for evaluating anti‐angiogenesis treatment in RCC patients. Reproduced with permission.[ 138 ] Copyright 2019, Elsevier. e) Tumor‐vasculature‐on a‐chip for drug‐loaded nanoparticles evaluation. Reproduced with permission.[ 144 ] Copyright 2018, American Chemical Society. f) 3D microfluidic cancer angiogenesis‐on‐a‐chip for RNAi‐based nanomedicine evaluation. Scale bar is 200 µm. Reproduced with permission.[ 116 ] Copyright 2021, American Chemical Society.](https://figures.cochat.ai/paper-figures/d7bbd9b41a4a4089a6f43cdefa2e6115/3d-biomimetic-models-to-reconstitute-tumor-microenvironment-in-vitro-spheroids-figure-6.jpg)
![Figure 7 Microfluidic modeling of blood–brain barrier. a) A 3D neurovascular microfluidic model consisting of HUVECs, rat neurons and astrocytes. Reproduced with permission.[ 147 ] Copyright 2017, Royal Society of Chemistry. b) A low permeability microfluidic BBB platform incorporating vascular networks and rat neural cells (neurons and astrocytes). Reproduced with permission.[ 148 ] Copyright 2017, Springer Nature. c) Schematic representation of a microfluidic brain angiogenesis model containing human brain endothelial cells and human neural cells. Scale bar = 100 µm. Reproduced with permission.[ 151 ] Copyright 2019, Wiley. d) Schematic view of 3D BBB microvascular network model mimicking the microvascular structure present in the brain environment. Scale bars:100 µm. Reproduced with permission.[ 152 ] Copyright 2018, Elsevier. e) Schematics of a 3D in vitro BBB microvascular model to study brain metastasis. Reproduced with permission.[ 134 ] Copyright 2021, American Association for the Advancement of Science. f) Microfluidic lumen‐based BBB model to evaluate drug response of GBM spheroids. Reproduced with permission.[ 159 ]Copyright 2021, Wiley‐VCH GmbH.](https://figures.cochat.ai/paper-figures/cbd6d44ead37449a878d8c521e06efa7/3d-biomimetic-models-to-reconstitute-tumor-microenvironment-in-vitro-spheroids-figure-7.jpg)
Verification
Claims the paper makes
23 Valid · 51 Not valid · 92 Not checked · 67 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“composite collagen‐alginate microcapsules laden with breast cancer cells (MCF‐7) were reported to create 3D vascularized tumor spheroids by suspending these core–shell microbeads inside an external stromal cell‐laden collagen matrix”
§ 3D Biomimetic Models to Reconstitute Tumor Microenvironment In Vitro: Spheroids, Organoids, and Tumor‐on‐a‐Chip > Strategies for Physiologically Relevant 3D Models > Spheroids
What the sources say
- Disputedcites [72] P. Agarwal, H. Wang, M. Sun, J. Xu, S. Zhao, Z. Liu, K. J. Gooch, Y. Zhao, X. Lu, X. He, ACS Nano 2017, 11, 6691. 28614653 PMC5663446 sourceExperimental — accuracy not yet measured
The Results section, “An efficient CTC assay for a unique clinical application” (page unavailable), says MCF-7 cells were seeded into tapered or cylindrical microwells to form clusters. The device description in Results identifies PDMS layers and microwell arrays, not collagen–alginate core–shell microbeads in a stromal collagen matrix. The reported culture method is therefore contrary to the one attributed to this paper. (LLM, conf=0.85)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In addition, the efficacy of programmed cell death protein‐1 (PD‐1) checkpoint immunotherapy was also evaluated on a patient‐derived GBM‐on‐a‐chip model, which consisted of two peripheral regions for vascular growth and middle regions for GBM growth.”
§ 3D Biomimetic Models to Reconstitute Tumor Microenvironment In Vitro: Spheroids, Organoids, and Tumor‐on‐a‐Chip > Strategies for Physiologically Relevant 3D Models > Tumor‐on‐a‐Chip
What the sources say
- Disputedcites [160] X. Cui, C. Ma, V. Vasudevaraja, J. Serrano, J. Tong, Y. Peng, M. Delorenzo, G. Shen, J. Frenster, R.‐T. T. Morales, Elife 2020, 9, e52253. 32909947 PMC7556869 sourceExperimental — accuracy not yet measured
The Conclusion describes a vascularized breast cancer cell extravasation model, not a patient-derived GBM-on-a-chip model. The Materials and Methods section on blocking and neutralization identifies IL-6R, IL-8R and MMP-3 inhibitors as the treatments tested, rather than PD-1 checkpoint immunotherapy. Page numbers are unavailable in our copy. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Vasculature lined with endothelial cells is essential for cancer growth and metastasis.[ 15 ]”
§ 3D Biomimetic Models to Reconstitute Tumor Microenvironment In Vitro: Spheroids, Organoids, and Tumor‐on‐a‐Chip > Overview of TME > Cellular Components
What the sources say
- Could not verifycites [15] R. K. Jain, Science 2005, 307, 58.15637262 sourceExperimental — accuracy not yet measured
The Hydrodynamic force section describes a co-culture model of endothelial and breast cancer cells used to study tumor angiogenesis. It does not say that endothelial-lined vasculature is essential for cancer growth or metastasis; searches for that assertion and for metastasis found no supporting passage. Page numbers were not available in our copy. (LLM, conf=0.74)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, there is a lack of systematic and comprehensive evaluation of these three kinds of tumor models, especially on the inclusion of ECM in cancer modeling.”
§ 3D Biomimetic Models to Reconstitute Tumor Microenvironment In Vitro: Spheroids, Organoids, and Tumor‐on‐a‐Chip > Introduction
What the sources say
- Could not verifycites [11] A. Sontheimer‐Phelps, B. A. Hassell, D. E. Ingber, Nat. Rev. Cancer 2019, 19, 65. 30647431 sourceExperimental — accuracy not yet measured
The Introduction discusses limitations of in vitro culture systems for hepatocellular carcinoma, and the Discussion focuses on a humanised mouse model and its immune microenvironment. Searches for spheroids, organoids, tumor-on-a-chip, extracellular matrix, and systematic evaluation found no passage addressing the claimed gap in evaluating those three models or their inclusion of ECM. No page numbers are available in our copy. (LLM, conf=0.74)
- Not checked — no full text of the sourcecites [12] S. M. Kang, D. Kim, J. H. Lee, S. Takayama, J. Y. Park, Adv. Healthcare Mater. 2021, 10, 2001284. PMC7855453 33185040
- Partly supportedcites [13] V. Veninga, E. E. Voest, Cancer Cell 2021, 39, 1190. 34416168 sourceExperimental — accuracy not yet measured
The “Limitations of organoids” section calls for standardized organoid protocols to enable comparison of results and for models that reflect extracellular-matrix effects. It does not say that systematic, comprehensive evaluation is lacking across spheroids, organoids, and tumor-on-a-chip, particularly with respect to ECM inclusion. (LLM, conf=0.78)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“However, such models are still unable to faithfully capture key aspects of the human tumor microenvironment (TME).[ 9 ]”
§ 3D Biomimetic Models to Reconstitute Tumor Microenvironment In Vitro: Spheroids, Organoids, and Tumor‐on‐a‐Chip > Introduction
What the sources say
- Could not verifycites [9] I. W. Mak, N. Evaniew, M. Ghert, Am. J. Transl. Res. 2014, 6, 114. 24489990 PMC3902221 sourceExperimental — accuracy not yet measured
The Background and Discussion passages address 3D cell cultures and how they mimic aspects of tumors in vivo, not humanized mouse models. A search of our copy for humanized mouse models and their ability to capture the tumor microenvironment found no passage addressing that claim; page numbers were not available. (LLM, conf=0.74)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
133 more claims · 42 with their cited sources checked
Create a free account to see all 233 claims and to verify the 29 references still open.
- It may state two separate claims as one. 74
- Probably not a substantial claim. 35
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Exploring the full spectrum of macrophage activation
Mosser, D. M., & Edwards, J. P. (2008) · Nature Reviews Immunology · doi:10.1038/nri2448 · Cited by 9,144
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632
Kalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Exploiting tumour hypoxia in cancer treatment
Brown, J. M., & Wilson, W. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1367 · Cited by 2,828
Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients
van de Wetering, M., Francies, H. E., Francis, J. M., Bounova, G., Iorio, F., Pronk, A., van Houdt, W., van Gorp, J., Taylor-Weiner, A., Kester, L., et al. (2015) · Cell · doi:10.1016/j.cell.2015.03.053 · Cited by 2,408
Research works printed but not linked: 7
- Mak I. W., 2014, Am. J. Transl. Res., 6, 114
- Bates D. O., 2002, Cancer Res., 62, 4123
- Subimerb C., 2010, Mol. Med. Rep., 3, 597
- Milosevic M., 2001, Cancer Res., 61, 6400
- 10.1371/journal.pone.0159013 · DOI · Paper page
- 10.1016/j.biomaterials.2018.07.048 · DOI · Paper page
- Sinha S., 2022, Adv. Healthcare Mater.
Cited by
Alternatives of Animal Models for Biomedical Research: a Comprehensive Review of Modern Approaches
Vashishat, A., Patel, P., Gupta, G. D., & Kurmi, B. D. (2024) · Stem Cell Reviews and Reports · doi:10.1007/s12015-024-10701-x · Cited by 126
Shen, X., Pan, D., Gong, Q., Gu, Z., & Luo, K. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.10.017 · Cited by 131
“To pursue an animal model that mimics a complex and realistic physiological or pathological environment in patient [75], patient-derived xenograft (PDX) models have been developed, and they have a number of advantages.”
BackgroundAdvancements in wearable sensors for cardiovascular disease detection for health monitoring
Khan, B., Riaz, Z., Ahmad, R. U. S., & Khoo, B. L. (2024) · Materials Science and Engineering R Reports · doi:10.1016/j.mser.2024.100804 · Cited by 96
Self-citationTumor-on-a-chip models combined with mini-tissues or organoids for engineering tumor tissues
Hwangbo, H., Chae, S., Kim, W.-J., Jo, S., & Kim, G. (2023) · Theranostics · doi:10.7150/thno.90093 · Cited by 73
“The utilization of cell spheroids in Tumor-on-Chip (TOC) technology presents several notable limitations [110].”
BackgroundPredictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway
Tufail, M., Hu, J.-J., Liang, J., He, C., Wan, W., Huang, Y., Jiang, C., Wu, H., & Li, N. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-023-04841-w · Cited by 80
“One of the major advantages of 3D orga-noids is their ability to recreate complex tumor micro-environments in a controlled laboratory environment [103].”
BackgroundBreaking the mold: 3D cell cultures reshaping the future of cancer research
Cordeiro, S. Z., Oliveira, B. B. P. P., Valente, R., Ferreira, D., Luz, A., Baptista, P. V., & Fernandes, A. R. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1507388 · Cited by 76
Factors Determining Epithelial-Mesenchymal Transition in Cancer Progression
Tomecka, P., Kunachowicz, D., Górczyńska, J., Gebuza, M., Kuźnicki, J., Skinderowicz, K., & Choromańska, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168972 · Cited by 67
“Various techniques, such as spinner flasks, hanging drop, magnetic levitation, ultra-low attachment plates, microwells, macroscopic 3D matrix, microgels, and 3D bioprinting, are utilized for their formation [245].”
BackgroundMethodInfluentialTumor-microenvironment-on-a-chip: the construction and application
Xu, H., Wen, J., Yang, J., Zhou, S., Li, Y., Xu, K., Li, W., & Li, S. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01884-4 · Cited by 65
“In fact, in the process of clinical oncology research, only about 5% of anti-cancer drugs enter phase I clinical trials and are finally approved by the FDA [3], and more than 80% of drug candidates stopped at the development stage [4].”
BackgroundMethodSelf-citationAdvancing cancer research through organoid technology
Zeng, G., Yu, Y., Wang, M., Liu, J., He, G., Yu, S., Yan, H., Yang, L., Li, H., & Peng, X. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05824-1 · Cited by 51
“Consequently, reconstructing tumor organ-oid models that incorporate TME elements in vitro is crucial for gaining a more comprehensive understanding of the original tumor characteristics [32].”
BackgroundRavi, K., Manoharan, T. J. M., Wang, K.-C., Pockaj, B. A., & Nikkhah, M. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122428 · Cited by 47
Machine learning-assisted exploration of multidrug-drug administration regimens for organoid arrays
Yakavets, I., Kheiri, S., Cruickshank, J., Hickman, R. J., Rakhshani, F., Aldeghi, M., Rajaonson, E. M., Young, E. W. K., Aspuru‐Guzik, A., Cescon, D. W., et al. (2025) · Science Advances · doi:10.1126/sciadv.adt1851 · Cited by 35
“Further developments will include the incorporation of stromal components, such as immune cells and cancer-associated fibroblasts ( 64 , 65 ), thus enhancing the predictive value of the integrated platform ( 66 , 67 ).”
González‐Callejo, P., García‐Astrain, C., Herrero‐Ruiz, A., Henriksen‐Lacey, M., Seras‐Franzoso, J., Abasolo, I., & Liz‐Marzán, L. M. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c04135 · Cited by 34
Momoli, C., Costa, B., Lenti, L., Tubertini, M., Parenti, M., Martella, E., Varchi, G., & Ferroni, C. (2025) · Cancers · doi:10.3390/cancers17040700 · Cited by 24
“The key point is that tumor organoids retain the essential structural and functional characteristics of real tumors, potentially offering a highly predictive in vitro model for guiding clinical decisions [27].”
InfluentialChoi, Y., Na, D., Yoon, G., Kim, J., Min, S., Yi, H., Cho, S., Cho, J. H., Lee, C., & Jang, J. (2025) · Advanced Science · doi:10.1002/advs.202411769 · Cited by 36
Madan, A., Saini, R., Dhiman, N., Juan, S., & Satapathy, M. K. (2025) · Organoids · doi:10.3390/organoids4040023 · Cited by 24
Tapeinos, C., Torrieri, G., Wang, S., Martins, J. P., & Santos, H. A. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.08.045 · Cited by 19
Metastatic brain tumors: from development to cutting‐edge treatment
Tanzhu, G., Chen, L., Ning, J., Xue, W., Wang, C., Xiao, G., Yang, J., & Zhou, R. (2024) · MedComm · doi:10.1002/mco2.70020 · Cited by 24
da Silva, P. B., Oliveira, R. J. A., Araújo, M., Caires, H. R., Bidarra, S. J., & Barrias, C. C. (2024) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2024.122363 · Cited by 23
Size-dependent penetration depth of colloidal nanoparticles into cell spheroids
Zhu, D., Brückner, D., Sosniok, M., Skiba, M., Feliu, N., Gallego, M., Liu, Y., Schulz, F., Falkenberg, G., Parak, W. J., et al. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115593 · Cited by 17
Casanova, C. R., Casanova, M. R., Reis, R. L., & Oliveira, J. M. (2024) · In vitro models · doi:10.1007/s44164-024-00072-5 · Cited by 18
Carnevali, F., Forciniti, S., Onesto, V., Siciliano, A. C., Iuele, H., Grasso, G., da Cruz, A. F., Serra, I., Depalma, N., D’Ugo, S., et al. (2024) · Advanced Therapeutics · doi:10.1002/adtp.202400351 · Cited by 20
Plesselova, S., Calar, K., Axemaker, H., Sahly, E., Bhagia, A., Faragher, J. L., Fink, D. M., & de la Puente, P. (2024) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-024-00817-y · Cited by 21
“…also a widely used model that can partially recapitulate the TME, but there is no fluid flow control or controlled compartmentalization, and the cells inside the spheroids are difficult to image, there is heterogeneity between samples, and not all cell types can naturally form them [23, 24, 26].”
BackgroundInfluentialDey, M. K., & Devireddy, R. V. (2025) · Biomimetics · doi:10.3390/biomimetics10010028 · Cited by 20
Gut microbiome in gastrointestinal neoplasms: from mechanisms to precision therapeutic strategies
Song, J., Zhang, W., & Wang, D. (2025) · Gut Pathogens · doi:10.1186/s13099-025-00734-z · Cited by 18
“By integrating immune cells, vascular endothelium, and fluid microenvironment, the establishment of a high-fidelity bionic "immune-tumor-microbiota" organoid model can effectively simulate the dynamic complexity of the TME in vivo [78].”
Tumoroids, a valid preclinical screening platform for monitoring cancer angiogenesis
Abbasi‐Malati, Z., Khanicheragh, P., Narmi, M. T., Mardi, N., Khosrowshahi, N. D., Hiradfar, A., Rezabakhsh, A., Sadeghsoltani, F., Rashidi, S., Chegeni, S. A., et al. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03880-4 · Cited by 17
“It is thought that tumoroids have relatively structural and functional cues like in vivo tumor masses, with a reliable platform for clinical decision-making [38].”
BackgroundYang, Q., Zhou, X., Lou, B., Zheng, N., Chen, J., & Yang, G. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.03.016 · Cited by 15
Self-citationZhu, G., Sun, Z., Liu, Y., Liu, J., Guo, L., Pei, G., Jiang, Y., Miao, B., Li, Z., Zhang, P., et al. (2025) · Advanced Science · doi:10.1002/advs.202501772 · Cited by 23
Navarro, P., Grazioso, T. P., Barquín, A., Barba, M., Yagüe, M., Millán, C., López, I., Sevillano, E., Quiralte, M., Fernández, P., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03437-0 · Cited by 16
“As a result, in recent years, systems aiming to replicate the biological behavior of tumors in vitro have multiplied [14, 15, 39].”
Plessis, D., Gouws, C., & Nieto, D. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1391259 · Cited by 13
Chehri, B., Liu, K., Vaseghi, G., Seyfoori, A., & Akbari, M. (2024) · Cells · doi:10.3390/cells13040363 · Cited by 13
Liu, M., Wang, Y., Wang, C., Li, P., Qiu, J., Yang, N., Sun, M., & Han, L. G. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202402321 · Cited by 12
Sorzabal-Bellido, I., Morales, X., Cortés‐Domínguez, I., Esparza, M., Grande, L., Castillo, P., Larumbe, S., Monteserín, M., Narayanan, S., Ponz‐Sarvisé, M., et al. (2025) · Gels · doi:10.3390/gels11070562 · Cited by 14
“These models may help bridge the translational gap posed by the scarcity of PDTOs and serve as ideal platforms to investigate tumor-ECM interactions in a physiologically relevant 3D context [19].”
Chen, Y., Lin, G., Wang, Z., He, J., Yang, G., Lin, Z., Gong, C., Liu, N., Li, F., Tong, D., et al. (2024) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2024.116668 · Cited by 10
Hao, J., Yu, X., Tang, K., Ma, X., Lu, H., & Wu, C. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.06.016 · Cited by 10
Zhao, Z., Feng, X., Wu, H., Chen, S., Ma, C., Guan, Z., Lei, L., Tang, K., Chen, X., Dong, Y. Q., et al. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-24-490 · Cited by 15
“To date, 3D cell culture models have been widely used in studies, such as drug discovery, disease modelling, and drug screening studies (23) .”
Organoids in Dynamic Culture: Microfluidics and 3D Printing Technologies
Su, X., Wang, M., Yuan, R., Guo, L., Han, Y., Huang, C., Li, A., Kaplan, D. L., & Wang, X. (2025) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.4c02245 · Cited by 12
Baskar, G., & Palaniyandi, T. (2025) · Acta Histochemica · doi:10.1016/j.acthis.2025.152282 · Cited by 12
Parihar, P., Sunildutt, N., Rahim, C. S. A., Samantasinghar, A., Lim, J., & Choi, K. H. (2024) · Advanced Therapeutics · doi:10.1002/adtp.202300410 · Cited by 10
Zimina, T. M., Sitkov, N. O., Газинурович, Г. К., Mikhailova, N., Combs, S. E., & Shevtsov, M. A. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1452298 · Cited by 15
Spheroid‐on‐a‐Chip Platforms for Tumor Microenvironment and Drug Development
Uzabakiriho, P. C., Jiajun, F., Nguchu, B. A., Iqbal, S., Manishimwe, C., & Shaw, P. M. (2025) · Advanced Materials Technologies · doi:10.1002/admt.202401821 · Cited by 9
Safarzadeh, S., Naghib, S. M., Takdehghan, G., Sarrami‐Forooshani, R., Roozbahani, M. H., Sharifianjazi, F., & Tavamaishvili, K. (2025) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2025.124245 · Cited by 12
Periosteum Organoid: Biomimetic Design Inspired From the Bone Healing Process
Hao, S., Wang, F., Huang, J., Xia, Z., Triffitt, J. T., Xu, C., Bai, L., & Su, J. (2025) · Exploration · doi:10.1002/exp.20240298 · Cited by 15
“…proliferation, differentiation and interaction of stem cells on the 3D scaffold material, and at the same time simulating the biochemical signals and mechanical stimuli in the periosteum microenvironment in vivo, periosteum organoids with high physiological similarity can be constructed [ 44, 45 ].”
Surendran, V., Safarulla, S., Griffith, C. M., Ali, R., Madan, A., Polacheck, W. J., & Chandrasekaran, A. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c01766 · Cited by 9
Shukla, A. K., Shukla, S., Suryawanshi, S. P., Upadhyay, A. M., Ray, N., Thiruppathi, G., Dutta, S. D., & Mongre, R. K. (2025) · Current Oncology · doi:10.3390/curroncol32120653 · Cited by 10
“Crucially, patient-derived tumor cells or biopsy samples can be used to create customized tumor avatars that act as ex vivo stand-ins for clinical judgment [40–43].”
Bria, J., Filardo, A., Vito, A. D., Torre, A. D., Lavano, A., Coscarella, I., Chiarella, E., Procopio, E., Egiziano, M. T., Longo, P., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311435 · Cited by 9
“The combination of spheroids/organoids with microfluidic technology is of particular interest for understanding tumor biology and accelerating the development of new therapies [66].”
From Spheroids to Tumor-on-a-Chip for Cancer Modeling and Therapeutic Testing
Lipreri, M. V., Totaro, M. T., Baldini, N., & Avnet, S. (2025) · Micromachines · doi:10.3390/mi16121343 · Cited by 10
“Therefore, developing more reliable and predictive models is essential to accelerate drug development and deepen the understanding of cancer biology [1].”
InfluentialBiomimetic nanosystems based on cell membranes (BNCMs) for cancer immunotherapy
Wang, Y., Huang, X., Wu, Q., & Gong, C. (2024) · MedComm – Biomaterials and Applications · doi:10.1002/mba2.106 · Cited by 8
Use of non-small cell lung cancer multicellular tumor spheroids to study the impact of chemotherapy
Hulo, P., Deshayes, S., Fresquet, J., Chené, A., Blandin, S., Boisgerault, N., Fonteneau, J., Treps, L., Denis, M. G., Bennouna, J., et al. (2024) · Respiratory Research · doi:10.1186/s12931-024-02791-5 · Cited by 10
Immunocompetent tumor-on-a-chip: A translational tool for drug screening and cancer therapy
Liang, A., Tao, T., Chen, J., Yang, Y., Zhou, X., Zhu, X. M., & Yu, G. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104716 · Cited by 6
Self-citationOrganoid technology in cervical cancer research
Ye, H., Song, L., Li, Q., Shen, C., He, Y., & Li, L. (2025) · American Journal of Cancer Research · doi:10.62347/fntd1712 · Cited by 7
“Commonly used animal models include transgenic models and PDX [65].”
Hong, C.-E., & Lyu, S. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17101258 · Cited by 17
Application and progress of 3D tumor models in breast cancer
Xu, J., Fang, W., Zhou, H., Jiang, R., Chen, Z., & Wang, X. (2024) · Biotechnology and Bioengineering · doi:10.1002/bit.28860 · Cited by 5
“3D tumor models, including scaffolds models, organoids, microfluidic devices, and 3D bioprinting technologies, hold immense promise for advancing research in immune ‐ oncology (Ao et al., 2022; Sun et al., 2022; Zhou et al., 2023).”
Kong, D., Yu, S., Heegsma, J., Blokzijl, T., Qin, T., Pan, Y., Blokzijl, H., de Meijer, V. E., Duan, Y., Faber, K. N., et al. (2026) · Journal of nanobiotechnology · doi:10.1186/s12951-026-04477-0 · Cited by 4
“…stem cells (ESCs), or induced pluripotent stem cells (iPSCs), have emerged as powerful tools to model human organ development, homeostasis, and strategies, which deciphers the mechanisms of liver diseases, bridging the gap between preclinical research and clinical translation. disease [9, 10].”
Clinical translational research on stem cell products: prospects and challenges
Chen, S., ZHANG, L., Ren, Y., Bai, X., Wei, X., Chai, M., 崔苏甦, Zhao, X., & Deng, H. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02582-y · Cited by 18
“374 Notably, because the paracrine action of MSCs plays a key role, the bioactive secretions of MSCs have good ef fi cacy and safety.”
Self-citationThe potential of hydrogel‐free tumoroids in head and neck squamous cell carcinoma
Wong, M. K. K., Vasani, S. S., Breik, O., Zhang, X., Kenny, L., & Punyadeera, C. (2024) · Cancer Medicine · doi:10.1002/cam4.70129 · Cited by 4
Du, Y., Yang, Y., Zheng, B., Zhang, Q., Zhou, S., & Zhao, L. (2025) · Oncogene · doi:10.1038/s41388-025-03273-8 · Cited by 4
“These in vitro 3D models can contain patient-derived cells and stroma, further re fl ecting the body ’ s own genetic information, drug sensitivity response, etc [109, 110].”
An Empirical Evaluation of Neural Network Architectures for 3D Spheroid Segmentation
Oudouar, F., Bir-Jmel, A., Grissette, H., Douiri, S. M., Himeur, Y., Miniaoui, S., Atalla, S., & Mansoor, W. (2025) · Computers · doi:10.3390/computers14030086 · Cited by 9
“Consequently, the segmentation of 3D spheroid images has emerged as a vital focus within the broader landscape of biomedical image analysis [9,10].”
Zhang, J., Sun, M., Zhang, F., Xuanyuan, T., Liu, X., Yu, D., & Liu, W. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202501105 · Cited by 5
Highly Strong and Transparent Hydrogel Elastomers Microfabricated for 3D Microphysiological Systems
Li, W., Li, L., He, H., Wang, P., Zhou, Z., Wu, W., Lv, D., Chen, Y., Pan, W., Zhou, X., et al. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c07880 · Cited by 3
Self-citationAranaz, P., Clavel-Millan, M., Gil‐Cardoso, K., González-Arceo, M., Hernández-González, D., Les, F., Salles, J., Amri, E., Arbonés-Mainar, J. M., Atgié, C., et al. (2025) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-025-01130-6 · Cited by 5
Zhang, X., Zhang, C., Zhang, Z., Zhang, X., & Wang, K. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1734244 · Cited by 5
Quadri, M., Iuliano, M., Rosa, P., Mangino, G., & Palazzo, E. (2025) · Life · doi:10.3390/life15081170 · Cited by 4
“They potentially offer a highly predictive in vitro model for guiding clinical decisions [148].”
Lee, D. S., Kang, J. I., Jeong, M., Byun, S., & Park, K. M. (2023) · Journal of Industrial and Engineering Chemistry · doi:10.1016/j.jiec.2023.11.029 · Cited by 5
Microsphere‐Enabled Modular Formation of Miniaturized In Vitro Breast Cancer Models
Wang, W., Zhang, L., O'Dell, R., Yin, Z., Yu, D., Chen, H., Liu, J., & Wang, H. (2023) · Small · doi:10.1002/smll.202307365 · Cited by 3
Self-citationZaky, M. Y., Lamloum, N. S., Ahmed, N. A., & Ahmed, O. M. (2025) · Springer eBooks · doi:10.1007/978-981-97-5742-8_5 · Cited by 3
Huang, Q., Xu, X., Halbiyat, Z., Wei, X., Wang, L., Ren, J., Xu, K., Huang, T., & Shuai, Q. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb00673b · Cited by 3
Matrix Mechanics Governs Mechano-Metabolic Adaptation across Cancer Grades in Bladder Spheroids
Metwally, S., Gil, D., Śmiałek, J., Pabijan, J., Wątor, G., Gnanachandran, K., Berardi, M., Kozłowski, Ł., Navdeep, & Lekka, M. (2026) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c25973 · Cited by 3
Melanoma treatment in the era of nanotechnology and precision medicine
da Cruz, A. F., Colella, F., Grasso, G., Onesto, V., Forciniti, S., Ortiz, B. B., Carnevali, F., Siciliano, A. C., Bove, R., dos Santos, J. G., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03851-8 · Cited by 5
Rahman, A., Jalouli, M., Al-Zharani, M., & Harrath, A. H. (2026) · Biomolecules · doi:10.3390/biom16020246 · Cited by 4
“Three-dimensional spheroids and organoids faithfully recapitulate the architecture, cellular composition, nutrient gradients, and drug penetration profiles of solid tumors [128].”
Wu, M., Xu, D., Dou, X., Zhou, Y., Lu, J., & Ge, Q. (2026) · Cell Signaling Inflammation & Disease · doi:10.1186/s44505-026-00004-y · Cited by 2
“Li et al. further highlighted that microfluidic-enabled 3D platforms facilitate precise modulation of immune cell recruitment and matrix composition [171– 173].”
Jiang, Y., Hao, M., Chen, S., Xie, Y., & Liu, K. (2024) · Analytical Methods · doi:10.1039/d4ay01343c · Cited by 3
3D cellular self-assembly on optical disc-imprinted nanopatterns
Lee, J., & Lim, C. T. (2024) · Lab on a Chip · doi:10.1039/d4lc00386a · Cited by 1
Isinelli, G., Failla, S., Plebani, R., & Prete, A. (2024) · Medicine International · doi:10.3892/mi.2024.212 · Cited by 1
Emerging Hydrophobized Surfaces for Rapid Fabrication of 3D Tumor Models
Monteiro, M. V., Carvalho, M. T., Moura, B. S., Gaspar, V. M., & Mano, J. F. (2025) · ACS Materials Letters · doi:10.1021/acsmaterialslett.4c02280 · Cited by 1
Ramesh, P., & Palaniappan, A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29260-6.00006-8 · Cited by 1
Machine Learning-Driven Anticancer Drug Discovery: From Virtual Screening to Preclinical Validation
Wang, Y. (2025) · Advances in Engineering Technology Research · doi:10.56028/aetr.14.1.1503.2025 · Cited by 1
Chen, C., Wu, P., Zhao, F., Han, Y., Lu, X., Yu, H., Huang, L., Wu, H., Chen, X., & Ma, H. (2025) · MedMat. · doi:10.1097/mm9.0000000000000028 · Cited by 2
Advances in microengineered platforms for 3D tumor production and modeling
Liu, X., Sun, M., Zhang, J., Xuanyuan, T., Yu, D., Wang, Z., Wang, Y. X., Deng, Z., & Liu, W. (2025) · Biomedical Microdevices · doi:10.1007/s10544-025-00778-7 · Cited by 1
“While its extreme complexity has been deeply depicted in numerous reviews (Rodrigues et al. 2021 ; Li et al. 2023; Ravi et al. 2024; Zhou et al. 2023; de Roode et al. 2024), there is an urgent need for researchers to focus cytokines (Harter et al. 2024; Xu et al. 2025).”
Dozzo, A., Dedeloudi, A., Lamprou, D. A., O’Driscoll, C. M., & Ryan, K. B. (2025) · Biomaterials and Biosystems · doi:10.1016/j.bbiosy.2025.100125 · Cited by 3
“Pivotal in the development of innovative and useful models includes the reproduction of the cells ’ natural microenvironment to mimic the relevant mechanical and biochemical cues inherent in the healthy and diseased state [114,115].”
Ye, Y., Srisai, D., & Barsky, S. H. (2025) · Biomedicines · doi:10.3390/biomedicines13122890 · Cited by 1
“Three-dimensional spheroid models recapitulate key features of solid tumors, bridging the gap between traditional 2D cell cultures and complex in vivo models [2–9].”
Use of Biomimetic Hydrogels and 3D Cancer Models for Biochemical and Cell Biological Assays
Guzman, A. (2026) · Methods in molecular biology · doi:10.1007/978-1-0716-4901-5_12 · Cited by 1
Tan, X., Huang, B., Yang, X., Wang, P., & Hu, L. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1746622 · Cited by 4
The application of experimental models for the drug discovery for digestive tumors
Zheng, L., Shuai, W., Liu, Y., Deng, Y., Bao, J., Hu, X., & Wang, G. (2026) · Molecular Cancer · doi:10.1186/s12943-025-02558-6 · Cited by 4
Tumor organoids as a revolutionary platform for advancing cancer nanomedicine
Wu, C., Chen, J., Zhang, C. M., Ji, J., Tan, Y., Liu, Z., Wu, Q., Zheng, X., Luo, K., & Xiao, K. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02702-w · Cited by 2
“Collectively, these elements critically influence tumor metabolism, angiogenesis, and immune evasion, playing pivotal roles in tumorigenesis, progression, and metastasis [112].”
Tong, Y.-W., Chen, A. C., Pai, P., & Lei, K. F. (2026) · Analytical Chemistry · doi:10.1021/acs.analchem.6c00457 · Cited by 1
Recent advances in nanomedicine for innovative oral cancer therapeutics—a review
Kaur, G., Arya, B., Mehra, P., & Singh, S. P. (2024) · Journal of Nanoparticle Research · doi:10.1007/s11051-024-06178-x · Cited by 1
Kuo, C., Liao, Y., & Lee, H. (2025) · Advanced NanoBiomed Research · doi:10.1002/anbr.202500060 · Cited by 2
Lab-on-a-chip – Reform, Perform, and Transform
Parihar, A., Khare, V., & Garg, M. (2024) · Royal Society of Chemistry eBooks · doi:10.1039/9781837673476-00001 · Cited by 1
Hyung, S., Ko, J., An, M., Kim, S. T., Park, S. H., Hong, J. Y., Lim, S. H., Kim, K., & Lee, J. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb00577a
Li, L., Qin, W., & Xie, J. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb01526j · Cited by 1
Zhang, Z., An, C., Dong, J., Zhang, X., Shen, T., Wang, D., Mi, X., Yue, S., Tan, X., & Zhang, Y. (2025) · Small · doi:10.1002/smll.202506809 · Cited by 3
Mechanical fingerprints in breast cancer research: A multimodal experimental approach
Niclot, F. B., Ferraro, R., Palo, V. D., Paolis, P. D., Taraballi, F., & Caserta, S. (2026) · Bioengineering & Translational Medicine · doi:10.1002/btm2.70148 · Cited by 2
“18,19 However, their biomechanical characterization remains challenging and underexplored.”
From 2D to 3D: transforming malignant bone tumor research with advanced culture models
He, Z., Huang, H., Fang, J., Liu, H., Yao, X., & Wu, H. (2025) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2400288
“These scaf ‐ folds can be derived from natural or synthetic sources and can be engineered to mimic the extracellular matrix (ECM) found in the TME (Li et al., 2023).”
3D Printing in Gastroenterology
Gardner, J. T., & Bensen, S. P. (2025) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002281
Kashani, M. P., Comelles, J., Barcelona, P., Torras, N., Diéguez, L., García-Díaz, M., & Martinez, E. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.08.698319
“Cell migration is one of the fundamental phenomena in cancer metastasis 39 .”
Blanquart, C., & Scherpereel, A. (2026) · Thorax · doi:10.1136/thorax-2025-223284 · Cited by 1
“78”
Wang, A., Xue, J., Cai, K., Lin, Z., & Shi, H. (2026) · Advanced Healthcare Materials · doi:10.1002/adhm.202505738
“After one week of incubation, multicellular spheroids can form spontaneously [36].”
Wang, S., Zhang, X., Ma, H., Lu, L., Jiang, H., Bai, Y., Chang, X., Wang, J., Yang, T., & Luo, G. (2026) · Communications Biology · doi:10.1038/s42003-026-09973-5
“Its low sample consumption and real-time monitoring compatibility further improve the ef fi ciency of drug screening and the feasibility of personalized therapy 8 .”
Zheng, F., Lan, Z., Chen, H., & Ma, M. (2026) · Biomedicines · doi:10.3390/biomedicines14040868
“Secondly, further validation in stromal cell-involved systems is essential for findings from in vitro scaffold-based OS models, owing to the highly heterogeneous nature of tumor tissue [9].”
Current Cell/Organoid and Animal Models for Primary Sclerosing Cholangitis
Yao, Q., Cheng, S., Pan, Q., Yu, J., & Hongcui, C. (2026) · Portal hypertension & cirrhosis · doi:10.1002/poh2.70048
Metadata
- Authors
- Li, W., Zhou, Z., Zhou, X., Khoo, B. L., Gunawan, R., Chin, Y. R., Zhang, L., Yi, C., Guan, X., & Yang, M.
- Affiliations
- City University of Hong Kong (HK)
- Sun Yat-sen University (CN)
- Department of Clinical Oncology State Key Laboratory for Liver Research The University of Hong Kong Hong Kong SAR 999077 China
- Corresponding author
- Yang, Mengsu
- ORCID
- Venue
- Advanced Healthcare Materials
- Publisher
- Wiley
- Published
- 2023-03-29
- Volume
- 12
- Issue
- 18
- Pages
- e2202609-e2202609
- ISSN
- 2192-2640 (ISSN-L)
- 2192-2659
- PMC
- PMC11468819
- OpenAlex
- W4324133297
- Cited by
- 119
- References
- 200
- Citations by year
- 2026: 36 · 2025: 44 · 2024: 33 · 2023: 6
- FWCI
- 2.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Advanced Healthcare Materials (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- The HKU Scholars Hub (University of Hong Kong) (submittedVersion, cc-by-nc-nd)
- CityU Scholars (submittedVersion, cc-by-nc)
- Funders
- Impact Fund
- City University of Hong Kong
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Physical Sciences › Materials Science › Biomaterials › Hydrogels: synthesis, properties, applications
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- tumor microenvironment, 3D tumor models, tumor spheroids, organoids, tumor-on-a-chip, biomimetic systems, hydrogels, microfluidics, preclinical drug screening, anticancer drug discovery, personalized medicine, animal-free model
- MeSH terms
- Animals, Neoplasms, Organoids, Spheroids, Cellular, Biomimetics, Lab-On-A-Chip Devices, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.